⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CELC News
Celcuity Inc. Common Stock
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
globenewswire.com
CELC
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
globenewswire.com
CELC
Celcuity To Participate in Upcoming Investor Conferences
globenewswire.com
CELC
Celcuity Appoints Charles Romp to its Board of Directors
globenewswire.com
CELC
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
CELC
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
globenewswire.com
CELC
CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials
globenewswire.com
PFE
AZN
UMBF
CELC
REGN
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
globenewswire.com
ONCY
SLS
CELC
RNXT
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report USA - English India - English
prnewswire.com
CLVT
LLY
GSK
JNJ
SNY
CELC
CRBP
BMY
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
globenewswire.com
CELC